Source: Annual Congress 2010 - Biomarkers for lung cancer
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
B. Ilievska Poposka, B. Zafirova, S. Jovanovska Crvenkovska, G. Petrusevska (Skopje, Fyrom). Her/2 neu and p53 expression in patients with non-small cell lung cancer predict shortened survival. Eur Respir J 2010; 36: Suppl. 54, 3238

Member's Comments

No comment yet.

Related content which might interest you: p-53 and HER2/neu expression in relation to chemotherapy response in patients with non-small cell lung cancer Source: Annual Congress 2007 - Novel genetic markers in pathology Year: 2007 ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer Source: Annual Congress 2009 - Genetics in the smokers corner: from inflammation in smokers via COPD to cancer Year: 2009 p53 and mdm2 expression in nonsmall cell lung cancer (NSCLC): the lack of prognostic relevance Source: Eur Respir J 2001; 18: Suppl. 33, 230s Year: 2001 The prognostic value of altered pRb and p53 protein expression in non-small cell lung cancer Source: Eur Respir J 2003; 22: Suppl. 45, 363s Year: 2003 MDM-2 gene amplification is associated with poor prognosis in operable non-small cell lung cancer (NSCLC) Source: Eur Respir J 2002; 20: Suppl. 38, 596s Year: 2002 HER-2/neu oncoprotein expression in nonsmall cell lung cancer Source: Eur Respir J 2002; 20: Suppl. 38, 230s Year: 2002 Expression of Her-2/neu and Bcl-2 in patients with non-small cell lung cancer Source: International Congress 2017 – Gene signatures in bronchial diseases Year: 2017 Fascin-1 overexpression predicts a poor prognosis in non-small cell lung cancer Source: International Congress 2017 – Lung cancer - clinical research: scientific pearls from the bedside Year: 2017 Characterization of patients with non-small cell lung cancer (NSCLC) relative to its EGFR mutational status Source: Annual Congress 2011 - Epidemiology of lung cancer and screening Year: 2011 The association of p53 and p21 expression with clinicopathological parameters and prognosis in non-small cell lung cancer Source: Annual Congress 2010 - Prognostic factors for lung cancer Year: 2010 A variant in LKB1 gene can predicts the clinical outcomes of chemotherapy in patients with non-small cell lung cancer Source: International Congress 2018 – Lung cancer: new aspects in diagnosis and management Year: 2018 Survivin expression in non-small cell lung cancer Source: Annual Congress 2010 - Recent developments of molecular pathology and functional genomics in non-neoplastic and neoplastic lung diseases Year: 2010 p53 mutations do not predict response to paclitaxel in metastatic non-small cell lung carcinoma Source: Annual Congress 2009 - Lung cancer biology Year: 2009 Prognostic value of p21 protein expression in non-small cell lung cancer Source: Eur Respir J 2004; 24: Suppl. 48, 674s Year: 2004 Prognostic significance of p53 and bcl-2 abnormalities in operable non-small cell lung cancer Source: Eur Respir J 2001; 17: 660-666 Year: 2001 Tumor specific MUC1 expression in operable lung cancer correlates with improved survival Source: Eur Respir J 2005; 26: Suppl. 49, 459s Year: 2005 Prognostic value of ERCC1 expression in advanced non-small cell lung cancer (NSCLC) Source: Annual Congress 2012 - Prognosis of lung cancer Year: 2012 Does long treatment delay affect survival in metastatic non-small cell lung cancer Source: Virtual Congress 2021 – Therapy of lung cancer Year: 2021 How to treat brain metastasis in patients with non-small cell lung carcinoma (NSCLC) and EGFR mutations Source: International Congress 2015 – How to treat brain metastases Year: 2015 One year survival differences of EGFR- and KRAS-mutated advanced non-small cell lung cancer (NSCLC) compared to the wildtype population Source: Annual Congress 2012 - Prognosis of lung cancer Year: 2012